Objetivos: El objetivo principal de esta Guía es recoger recomendaciones concretas basadas en los resultados de la literatura científica para tratar a pacientes con un trastorno mental grave y un consumo de sustancias atendidos en centros de tratamiento hospitalarios y ambulatorios. Incluye: 1) Recomen...
Trastornos Mentales/tratamiento farmacológico,
Trastornos Relacionados con Sustancias/tratamiento farmacológico,
Terapia Psicoanalítica,
Antidepresivos/uso terapéutico,
Antipsicóticos/uso terapéutico,
Clozapina/uso terapéutico,
Agonistas de Dopamina/uso terapéutico,
Naltrexona/uso terapéutico,
Bupropión/uso terapéutico,
Vareniclina/uso terapéutico,
Inhibidores de la Captación de Serotonina/uso terapéutico,
Desipramina/uso terapéutico,
Disulfiram/uso terapéutico,
Buspirona/uso terapéutico
In 2015 WHO updated the mhGAP guidelines, first issued in 2009, for the management of mental, neurological and substance use (MNS) disorders. In order to reduce the gap and to enhance the capacity of Member States to respond to the growing challenge, the World Health Organization (WHO) developed the Ment...
These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder. They have been develope...
These guidelines use a stepped care approach to treating drug dependence. This approach acknowledges that different people require different interventions around their drug use. These guidelines take a public health approach to drug use and dependence. This approach recognises that the health of one indi...
These guidelines have been developed in response to the resolution Guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids of the United Nations Economic and Social Council (ECOSOC). The aims of these guidelines are to reduce global barriers to the effective treat...
mhGAP is WHO’s action plan to scale up services for mental, neurological and substance use disorders for countries especially with low and lower middle incomes. The priority conditions addressed by mhGAP are: depression, schizophrenia and other psychotic disorders, suicide, epilepsy, dementia, disorder...
These guidelines aim to provide a strategic approach to reducing morbidity and mortality related to TB and HIV among at-risk drug users and their communities in a way that promotes holistic and person-centered services. They are intended for professionals dealing with the drug users who have the most pro...
